No Data
McLeod, Hope and others [Emerging Markets Press Release]
<3622> Net income forecast revised, current fiscal year net income outlook 0.115 billion yen←0.205 billion yen <3900> CLOCK・IT, which handles CloudWorks system integration, acquired shares and became a subsidiary <4594> Brightpass 17th new subscription rights (with revised exercise price clause) significantly exercised, with 1.5 million shares of stock issued from January 1st <4892> Recognized approximately 1.7 billion yen of government grant revenue as non-operating income <6081> AlliedArch consolidated
Three points to focus on in the morning session ~ Strong buying interest waiting for pullbacks in the context of a weak yen trend ~
In the morning session of 3 days ago, the following 3 points should be noted: - In the context of a weak yen, there is strong buying interest waiting for dips. - Seibu Holdings: upward revision on 3/25, operating profit 45 billion yen (previously 40 billion yen). - Morning session focal points: harmonic, mass production of decelerators for humanoid robots, strategic investment of 10 billion yen. - In the context of a weak yen, there is strong buying interest waiting for dips. While there is a possibility of increasing stagnation in the Japanese stock market on the 3rd day after the buying spree, a market development with strong buying interest in dips is expected. Following the U.S. market on the 2nd day.
YS Food, etc., [Stock Picks Based on Volume Changes].
Stock Closing Price Change from Previous Day Volume ＜4892＞Sai Fuse 617 14 562,800 ＜4317＞Ray 440 12 59,800 ＜2518＞NF Japan Female Activity 1581 25 22,633 ＜2555＞Tokyo Stock Exchange REIT ETF 1822 11 18,890 ＜1730＞Asahi Foam 608
Noil Immun, Carna Bio, and others.
Collaborative relationship company stock sale profit of 6.4 billion yen expected to be recorded as special profit for <3908> Capital increase through third-party allotment by Carnabyo (1,056,00 shares) for <4572> Approximately 1.4 billion yen in subsidy income from Saifyuz to be recorded as non-operating income for <4892> Takara Bio <4974> and business alliance in the development of Noil Immun NIB103 <4893> <7776> Seaseed's clinical trial start date for homologous chondrocyte sheet (CLS2901C) is expected to be delayed.
Jelly Beans Group, Siphuse, etc.
<2164> Region Newspaper Co., Ltd. Shareholding ratio 9.95% → 9.95% Reporting obligation start date 2024/09/09 <3070> Jelly Beans Group Milestone Capital Management Co., Ltd. Shareholding ratio 8.12% → 7.43% Reporting obligation start date 2024/09/06 <4892> Cyfuse SBI Ventures Two Co., Ltd. Shareholding ratio
Insider decrases its stake in Cyfuse Biomedical KK(4892.JP) to 11.11%
On Sep 11, SBI Ventures Two株式会社 and related parties submitted the Change Report to Ministry of Finance. The report shows that SBI Ventures Two株式会社 and related parties decreased their holdings in $
No Data
No Data